Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Marcelo Garrido's publication output changed over time?
ScholarIQpublication output · 2015–2021
Output grew0% over the shown period — from 1 works in 2015 to 1 in 2021.
1
1
20152021
What are the most-cited papers on Marcelo Garrido?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
The Lancet. 20156,550 Citations
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Rubén Dario Kowalyszyn, Michalis V. Karamouzis, Ricardo Brugés, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani
The Lancet. 20212,981 CitationsOPEN ACCESS
Related on ScholarIQ
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Paper
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Paper
Cancer Immunotherapy and Biomarkers
Topic